

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**TYK Medicines, Inc**

**浙江同源康醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2410)**

## **POLL RESULTS OF 2025 SECOND EXTRAORDINARY GENERAL MEETING HELD ON OCTOBER 30, 2025**

The board of directors (the “**Board**”) of TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”) is pleased to announce that the poll results of the 2025 second extraordinary general meeting (the “**EGM**”) of the Company was convened at 1:30 p.m. on Thursday, October 30, 2025 at 8th Floor, Building T2, China Eastern Binjiang Center, No. 277 Longlan Road, Xuhui District, Shanghai, the PRC. References are made to the notice of the EGM and the circular of the Company dated October 14, 2025 (the “**Circular**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Circular.

### **POLL RESULTS OF 2025 SECOND EXTRAORDINARY GENERAL MEETING**

The EGM was convened by the Board and chaired by Dr. WU Yusheng, the Chairman of the Board. All of the Directors, namely, Dr. WU Yusheng, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao, Dr. ZHU Xiangyang, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua attended the EGM in person or by electronics means. The convening of and the procedures for holding the EGM and the voting procedures at the EGM were in compliance with the requirements of the PRC Company Law and the Articles of Association. The poll results of the resolutions proposed at the EGM are as follows:

<b>Ordinary Resolutions</b>		<b>Number of votes (%)</b>		
		<b>For</b>	<b>Against</b>	<b>Abstain</b>
1.	To consider and approve the proposed amendments to the Rules of Procedure for the Board of Directors.	133,127,002 (99.99%)	0 (0.00%)	10,500 (0.01%)
2.	To consider and approve the proposed amendments to the Rules of Procedure for Shareholders' General Meetings.	128,456,002 (96.48%)	4,671,000 (3.51%)	10,500 (0.01%)

Special Resolutions		Number of votes (%)		
		For	Against	Abstain
3.	To consider and approve the proposed amendments to the Articles of Association and the proposed abolishment of the Board of Supervisors.	133,127,002 (99.99%)	0 (0.00%)	10,500 (0.01%)
4.	To consider and approve the proposed adoption of the 2025 H Share Incentive Scheme.	128,246,502 (96.32%)	4,880,500 (3.67%)	10,500 (0.01%)

*Note: All percentages are rounded up to two decimal places.*

Please refer to the Circular for details of each of the above resolutions.

As more than half of the votes were cast in favour of ordinary resolutions (1) to (2) and more than two thirds of the votes were cast in favour of special resolutions (3) to (4), the above ordinary resolutions (1) to (2) and special resolutions (3) to (4) were duly passed at the EGM by way of poll by the Shareholders. The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

As at the date of the EGM, the total number of issued Shares was 380,065,818 Shares, comprising 375,457,818 H Shares and 4,608,000 Unlisted Shares. The holders of all such Shares were entitled to attend and vote for or against or abstain from all the resolutions proposed at the EGM. To the best of the Director's knowledge, information and belief, and according to applicable PRC law, regulations and regulatory requirements, none of the Shareholders are required to abstain from voting at the EGM pursuant to the Listing Rules. There were no Shares entitling Shareholders to attend the EGM and abstain from voting in favour of the resolutions pursuant to the Rule 13.40 of the Listing Rules. No Shareholders have stated their intention in the Circular to vote against any resolutions or to abstain from voting at the EGM. There were no Shares actually voted but excluded from calculating the poll results of the resolutions proposed at the EGM. As of the date of the EGM, there were (i) no H Shares repurchased and held by the Company in treasury ("**Treasury Shares**") (including any Treasury Shares held or deposited with the Central Clearing and Settlement System operated by Hong Kong Securities Clearing Company Limited) and as such no voting rights of the Treasury Shares have been exercised at the EGM; and (ii) no repurchased Shares and therefore no Shares are pending cancellation and should be excluded from the total number of issued Shares entitled to attend and vote on all the resolutions at the EGM.

The Shareholders or their proxies present at the EGM held 133,137,502 Shares with voting rights in aggregate, representing approximately 35.03% of the total number of issued Shares as of the date of the EGM.

By Order of the Board  
**TYK Medicines, Inc**  
(浙江同源康醫藥股份有限公司)

**Dr. WU Yusheng**  
*Chairman, Executive Director and Chief Executive Officer*

Hong Kong, October 30, 2025

*As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.*